QR-421a: Showing Benefits on One out of Four Usher Syndrome patients

Original article on AP News QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events — QR-421a is the second ophthalmology program where clinical activity was predicted by translational models, further validating the platform — COVID-19 pandemic expected to impact timelines for the pipeline — ProQR anticipates its cash runway will fund operations into H2 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass.,
Read